At Harshamitra Research Centre, our Research and Development (R&D) division is committed to pioneering clinical research and advancing medical knowledge to improve patient care. We engage in cutting-edge studies across multiple disciplines, including oncology, pharmacology, and epidemiology. Our research efforts are conducted through our in-house studies, collaborative research units, and external partnerships.

Our Research Initiatives

Our Own Studies & Trials

We undertake independent research projects to explore innovative treatments and improve medical outcomes. Some of our key studies include:

  1. Mindfulness Study– Completed; paper publication in progress.
  2. Hydrogen Trial– Completed; paper publication in progress.
  3. Demographic Study– Ongoing.
  4. COVID-19 LDRT Follow-up.– Ongoing.
  5. Rectum Brachytherapy– Case series paper publication in progress.
tab-image
tab-image

Clinical Research Unit

Our Clinical Research Unit, led by a dedicated team of researchers, is involved in industry-sponsored and investigator-initiated trials.

Ongoing Trials:

  1. Azacitidine 300 mg Trials– Sponsored by Lotus Pharma for Acute Myeloid Leukemia (AML).
  2. Triple Negative Breast Cancer Study.
  3. Capecitabine 500 mg Bioequivalence Study – Phase II.
  4. Overactive Bladder – Prostatic Hyperplasia (BPH) Study.

Completed Trials:

  1. Azacitidine 300 mg Trials (Veeda I & II, Lambda) for AML.
  2. Olaparib 150 mg Study.
  3. Bipolar II Disorder – Psychiatry Research.
  4. Paclitaxel Study for Metastatic Breast Cancer.
  5. Capecitabine 500 mg Bioequivalence Study – Phase I.
  6. Aceclofenac Study.

Collaborative Research (Other Research Units)

We collaborate with research teams across India, working on trials that include:

Ongoing Trials:

  1. Biomarkers Trial (Blood and Tissue Sample Analysis)
  2. Fluid Collection Trial
  3. Carcinoma of Mammary Glands Trial– about to be completely
tab-image
tab-image

Ethics Committee & Regulatory Compliance

Our Ethics Committee (EC) ensures all clinical trials comply with the New Drugs and Clinical Trials Rules, 2019, and Good Clinical Practice (GCP) guidelines. We are officially registered under:

  1. EC Registration No.: ECR/926/Inst/TN/2017/RR-20
  2. Validity: 13-Oct-2020 to 12-Oct-2025
  3. Committee Composition: Medical scientists, clinicians, legal experts, social scientists, and laypersons, ensuring ethical oversight in all research activities.

Our Ethics Committee plays a critical role in:

  1. Reviewing and approving clinical trial protocols.
  2. Ensuring the safety, rights, and well-being of trial participants.
  3. Conducting periodic reviews and audits of ongoing trials.

Commitment to Innovation and Patient Care

Through our R&D initiatives, we strive to contribute to medical advancements that enhance patient outcomes and offer new treatment possibilities. Our commitment to rigorous scientific research, ethical practices, and continuous innovation ensures that we remain at the forefront of clinical excellence.

tab-image

Publications